Search results
Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
Retina UK is delighted to have awarded a new three-year research grant to Prof Majlinda Lako at Newcastle University for a project entitled: To establish AAV.PRPF31 gene augmentation in PRPF31-deficient RPE and photoreceptor cells and assess its efficacy in restoring RPE and photoreceptor function.
Early results from clinical testing of a gene therapy to treat X-linked retinitis pigmentosa (XLRP) have shown partial reversal of sight loss in some patients.
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Nikolas is a bioinformatician, who uses computer power to tackle medical research challenges.
Retina UK is delighted to announce that it has awarded three new research grants worth more than £870,000.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
February is Retinitis Pigmentosa Awareness Month and we'd love you to get involved to enhance the work of Retina UK, as we continue to support those who are living with retinitis pigmentosa and other inherited sight loss conditions.
